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Abstract:  Even though some medications have the potential to slow the progress of 
atherosclerosis and development of CVD, there are many at-risk individuals who continue 
to resist the benefits that are available by not following the advice of medical professionals. 
Non-adherence to prescribed drug regimens is a pervasive medical problem that negatively 
affects treatment outcomes. Information from standardized interviews of 5301 African 
Americans participating in the Jackson Heart Study  was examined to determine the 
association between demographic parameters, behavior including adherence to prescribed 
medical regimens, and health outcomes. Data were also collected at Annual Follow-Up and 
Surveillance visits. During the two weeks prior to the examination visit, almost 52% of the 
participants reported taking blood pressure medication, 14% took cholesterol medication, 
16% took medication for diabetes, and 19% took blood thinning medication. Of those who 
did not take the prescribed medications, the reasons given were the following: 47% were in 
a hurry, too busy, or forgot to take medications;  23% were trying to do without 
medications;  18% had no money to purchase medications;  19% indicated that the 
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medications made them feel bad; 17% felt that they could not carry out daily functions when 
taking medications. The African American population can benefit from heightened 
awareness of the risk factors that are associated with CVD and the benefits of following a 
prescribed treatment  regimen. Unacceptable secondary effects of prescribed medication 
comprised  an  important cause of non-compliance.  Encouragement of this population to 
communicate with their healthcare providers to ensure that medication regimens are better 
tolerated could increase compliance and improve health outcomes.  
Keywords:  medication  use;  minority; African-Americans; Jackson Heart Study; 
cardiovascular disease 
 
1. Introduction  
In recent years, medical science has reported some degree of progress in the struggle against 
cardiovascular disease (CVD), but it remains a major health concern, accounting for approximately  
1 million deaths in the United States each year [1]. Progress has been attributed to strategic active 
prevention of the various risk factors, improvements in healthcare, and the development and use of new 
therapies. Even though the potential of some medications to slow the progress of atherosclerosis and 
the development of CVD has received wide exposure, large numbers of individuals resist medication 
adherence and fail to take advantage of the potential benefits of a daily medical   
regimen [2]. Medication non-adherence reduces the effectiveness
 of therapies.  
Munger, Van Tassell, & LaFleur [3] have referred to non-adherence as an unrecognized risk factor 
and as a pervasive medical problem that negatively affects treatment outcomes. One third to one half of 
patients do not comply with prescribed treatment regimens  [4-6].  Non-adherent
 patients  have also 
exhibited  higher glycosylated hemoglobin, systolic and diastolic
  blood pressure, and low-density 
lipoprotein cholesterol levels  [7].  Non-adherence has been identified as a frequent cause of relapse 
among patients
 [8]. Immune suppression therapy non-adherence is the leading
 avoidable cause of renal 
transplant failure.  Renal transplant patients particularly at risk may be those who have
 a history of  
non-adherence to medical advice [9].  Between one third and two thirds of all medication-related 
hospital admissions are attributed to non-adherence [10], costing the healthcare system an estimated  
$ 792 million to $1 billion annually [4,11]. 
In patients with hypertension, medication non-adherence is a significant, often unrecognized, risk 
factor that contributes to poor blood pressure control, which could later lead to the development of 
more serious disorders like heart failure, coronary heart disease, renal insufficiency, and stroke [3]. One 
study found that fewer than
 50% of patients who were prescribed statin medications were adherent
 12 
months after initiating treatment, and other research has demonstrated that non-adherence
 to oral 
hypoglycemics and antihypertensive medications has been
 associated with higher HbA1c and BP levels, 
respectively [12,13].  
The practice of non-adherence results in only 59% of people with hypertension regularly receiving 
effective treatment [14]. Hypertension increases the chances for stroke, end-stage renal disease, and 
heart failure, as well as contributes to the prevalence of insulin resistance, lipid abnormalities, changes in Int. J. Environ. Res. Public Health 2011, 8                 
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renal function, endocrine abnormalities, obesity, left ventricular hypertrophy, diastolic dysfunction, and 
abnormalities in vascular structure and elasticity [15]. Even though effective antihypertensive
 drugs are 
available, poor adherence to prescribed
 treatment remains a major cause of uncontrolled blood pressure 
that could result in target organ damage
 and increased cardiovascular risk. Medication adherence rates 
have been classified in ranges from 35% to 97% [16,17].  
Older adults are prescribed more medication
 than any other group, and poor adherence is a common 
reason
  for  their  non-response to medication [18].  More needs to be done to promote adherence, 
heighten awareness, and understand the reasons for the resistance to prescribed treatment regimen in the 
African American community with its high prevalence of CVD [19]. Social support has been shown to 
have both direct
 and indirect associations with
 medical adherence [20]. It is important for individuals to 
understand that those who have had a heart attack previously are at an increased risk of death when 
they do not adhere to the prescribed medication [6], especially since about one third to two thirds of all 
patients admitted to the hospital with medication-related  problems are those who have not been 
following the prescribed medication program [10,21]. In one study, about half of the patients who were 
prescribed an antihypertensive
 drug had stopped taking it within one year. The likelihood that a patient 
would discontinue treatment
 early was inversely related to the quality of regular execution of the dosing 
regimen [22]. Therapeutic
 approaches that are designed to improve treatment adherence attitudes and
 
behaviors should address an individual’s risk practices and the potential negative health outcomes [8]. 
Few  studies have comprehensively examined adherence to medication regimen in   
African-Americans and possible health outcomes associated with medication adherence when diagnosed 
with disease. One study reported that even though African Americans tend to have higher rates of 
diabetes and disease-related complications, they had a 12% lower medication  adherence rate than 
whites. These low rates of adherence have been linked to lower socioeconomic status and to lower 
levels of education.  African-Americans with type  2 diabetes appear to be less likely than   
whites to take prescribed medications [23]. The Jackson Heart Study has collected data on a large 
cohort of African-Americans and provides an appropriate mechanism to explore medication adherence 
in this group. 
The aim of this study was to assess CVD diagnoses and adherence to CVD medications, and to 
identify
 predictors of hospitalization for CVD conditions. It was hypothesized that JHS participants who 
adhered to a prescribed medical regimen for a diagnosed CVD condition would encounter less 
deterioration in CVD health status (as measured by hospitalization) than those who did not adhere to a 
prescribed medical regimen for a diagnosed CVD condition. The study examined the following research 
questions: 
(1) What is the extent of cardiovascular disease diagnoses in the Jackson Heart Study cohort?  
(2) What is the extent of medication adherence in the Jackson Heart Study cohort?  
(3) What are the predictors of cardiovascular disease hospitalization among JHS participants? 
(4) What are the reasons for non-adherence in the JHS? Int. J. Environ. Res. Public Health 2011, 8                 
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2. Experimental Section 
2.1. Methods 
Baseline interview data collected from 5301 African Americans,  living in the tri-county area of 
metropolitan Jackson, Mississippi; Hinds, Madison and Rankin counties and participating in the Jackson 
Heart Study, were analyzed. The Jackson Heart Study (JHS) is the largest single-site epidemiological 
study of cardiovascular disease on African-Americans on record. A systematic review of the JHS data 
was made focusing on medication use, CVD health status, and demographic parameters to examine 
practices and behaviors of the participants and association between those practices and the primary 
health outcome, hospitalization.  Details of the JHS, its   
development, participants, and overall procedures are described further by Addison et al. [24] and 
Campbell-Jenkins et al. [25] in earlier publications. 
Demographic variables of the JHS participants (age, education level, age, income, and county of 
residence) were extracted from the Household Enumeration Form (HEF) and Personal Data—
Socioeconomic Status Form (PDS). Cardiovascular
 conditions of JHS participants at baseline (high 
blood pressure, high cholesterol, heart attack, diabetes, and stroke) were obtained from the Personal 
and Family History Form (PFHA). On this form, participants responded with a “yes”, “no”, or “don’t 
know” answer about whether they were told by a physician that they had certain diseases. JHS 
participants’ CVD medication use was obtained from the Medication Survey Form (MSRA). On this 
form, the participants were again asked to respond with a “with a “yes”, “no”, or “don’t know” answer 
about whether they had taken medication for high blood pressure, high cholesterol, heart attack, 
diabetes, or stroke during the two weeks prior to coming to the Exam Center for their clinic exams. 
Self-report of adherence
 to medications is a useful and expedient way of assessing
 adherence [26]. JHS 
participants’ reasons for not taking the doctor-prescribed medication were also elicited from the MSRA. 
Participants were given a list of potential reasons cited that prevented people from taking medication as 
prescribed, and asked to indicate with a “yes”, “no”, or “don’t know” answer. The primary study 
outcome was self-reported hospitalization for CVD which was extracted from the participants’ annual 
follow-up interviews.  Subjects were asked at 1-year  follow-up interviews whether they had been 
hospitalized for CVD during the previous 12 months.  
2.2. Statistical Analysis 
 We calculated CVD health status among participants by age, gender, education, and income. We 
ascertained adherence to medication among participants with self-reported CVD-related morbidity by 
age, gender, education, and income. Differences in the occurrence of hospitalizations between 
participants who adhere to a medical regimen and those who do not were assessed. Because medication 
non-adherence may act on the causal pathway between a risk factor and subsequent hospitalization for 
CVD, this study evaluated medication adherence as a risk factor for CVD-related hospitalization, taking 
baseline CVD conditions into account.  We analyzed the binary outcome of hospitalization or no-
hospitalization for CVD-related health status using logistic regression analysis, with separate models for 
each predictor variable  to assess the association between the medication adherence of diagnosed Int. J. Environ. Res. Public Health 2011, 8                 
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participants. All statistical tests were considered
 significant at the 0.05 level. The SAS version 9.2 (SAS
 
Institute, Cary, North Carolina) and SPSS 18.0 were used for all   
statistical
 analyses, which were performed independently at Jackson Heart Study Coordinating Center 
(Jackson, Mississippi). 
3. Results and Discussion 
3.1. Results 
In Table 1, the distribution of self-reported cardiovascular conditions of the JHS participants at 
baseline are presented. The JHS participants provided responses to the questions regarding whether 
they were told by a doctor that they had high blood pressure, high cholesterol, heart attack, diabetes, 
kidney problems, or stroke. The highest number of high blood pressure diagnoses occurred with the 
older participants aged 65 and older. However, it is noteworthy that over 14.0% of the youngest age 
group 21–34 indicated that they were diagnosed with high blood pressure. High cholesterol diagnoses 
seem to occur more frequently in the over 65 year age group, with almost 4.0% of the youngest group, 
21–34, also classified in this category. The rate of diabetes diagnoses was higher than the national 
average in the JHS participants over the age of 45. JHS participants aged 21–34 (4.8%) and 35–44 
(7.3%) had a significant number who were diagnosed with diabetes. The largest group of diagnoses 
with kidney problems was the over 85 group (26.7%). However, the 21–34 age group (8.4%) surfaced 
as having a larger number of kidney problem diagnoses than participants 35–74. Only the 75–84 age 
group with 9.9% of the cases was higher than the 21–34 age group, with the exception of the over 85 
age category with its 26.7%. The diagnosis of stroke appeared to occur with more frequency in the 
older age groups, with the over 85 group having the greatest representation (20.0%). 
A comparison of the diagnoses made by a doctor based on gender showed that females were more 
likely than males to have diagnoses in four of the six categories examined. Females were also more 
likely than males to have high blood pressure (58.3% to 49.7%), high cholesterol (28.8% to 25.6%), 
diabetes (18.4% to 15.3%), and kidney problems (5.6% to 4.3%). The male JHS participants had more 
diagnoses in the area of heart attacks (6.4% to 4.1%) and strokes (4.2% to 3.4%). 
We examined the diagnoses made by a doctor based on education level. Greater educational 
attainment seemed to translate into a lower degree of CVD related diagnoses. In every category of 
diagnoses, the JHS participants with the lowest level of education (< high school) experienced the 
greatest degree of medical issues, leading the way with blood pressure diagnoses of 70.8% and diabetes 
diagnoses of 26.2%. This group also had a stroke diagnosis rate of 8.4% compared to 1.9% for the 
participants who had a Bachelors degree and above and a heart attack rate of 9.3% compared to the 
2.9% for the group with a Bachelors degree or above. In all of these disease categories, the data reveal 
that the amount of CVD related diagnoses occurs more frequently the lower one appears on the 
education level spectrum. Income level seems to have played a part in the distribution of the   
CVD-related diagnoses as reported by the JHS participants. In all of the disease categories, JHS 
participants in the lowest income levels reported a larger number of diagnoses of high blood pressure, 
cholesterol, heart problems, diabetes, kidney problems, and strokes. High cholesterol is the only illness 
category where all of the JHS participants seem to be affected more evenly. Int. J. Environ. Res. Public Health 2011, 8                 
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Table 1. Self-reported cardiovascular
 conditions of JHS participants at baseline. 
 
 
Characteristics 
Told by 
Doctor Had 
High Blood 
Pressure 
Told by 
Doctor Had 
High 
Cholesterol 
Told by 
Doctor 
Had 
Heart 
Attack 
Told by 
Doctor Had 
Diabetes 
Told by 
Doctor 
Had 
Kidney 
Problems 
Told by 
Doctor Had 
Stroke 
p < 0.05  p > 0.05  p > 0.05  p > 0.05  p> 0.05  p > 0.05 
Age  N  %  N  %  N  %  N  %  N  %  N  %  N  % 
21–34  251  4.7  36  14.3  10  3.9  0  0.0  12  4. 8  21  8.4  1  0.4 
35–44  1008  19.0  340  33.7  159  15.8  9  0.9  74  7.3  31  3.1  7  0.7 
45–54  1302  24. 6  620  47.7  338  26.0  50  3.9  176  13.6  54  4.2  19  1.5 
55–64  1436  27.1  949  56.2  463  32.3  88  6.1  318  22.2  72  5.0  72  5.0 
65–74  996  18.8  741  74.6  383  38.6  85  8.6  256  25.8  60  6.0  75  7.6 
75–84  283  5.5  226  77.0  102  34.9  29  9.9  75  25.7  29  9.9  18  6.2 
Over 85  15  0.3  10  66.7  5  33.3  1  6.7  1  6.7  4  26.7  3  20.0 
Sex  p > 0.05  p > 0.05  p > 0.05  p > 0.05  p > 0.05  p > 0.05 
Female  3360  63.4  1958  58.3  965  28.8  138  4.1  616  18.4  188  5.6  113  3.4 
Male  1941  36.6  964  49.7  495  25.6  124  6.4  296  15.3  83  4.3  82  4.2 
Education Level  p > 0.05  p < 0.05  p < 0.05  p > 0.05  p > 0.05  p < 0.05 
Less than High 
School 
973  18.42  690  70.8  329  32.9  90  9.3  255  26.2  81  8.3  82  8.4 
High 
School/GED 
1064  20.15  630  59.2  289  27.2  64  6.0  183  17.2  63  5.9  39  3.7 
>High 
School,< 
Bachelors 
1525  28.88  749  49.1  376  24.7  56  3.7  232  15.2  63  5.9  41  2.7 
Bachelors 
degree or 
higher 
1719  32.55  843  49.1  462  26.9  51  2.9  239  13.9  62  3.6  33  1.9 
Family Income  p > 0.05  p > 0.05  p > 0.05  p > 0.05  p > 0.05  p > 0.05 
Low  701  15.64  432  61.6  201  28.7  57  8.1  160  22.8  64  9.1  52  7.4 
Lower–Middle  1131  25.24  691  61.1  328  29.0  65  5.8  219  19.3  61  5.4  60  6.3 
Upper–Middle  1328  29.64  690  52.0  338  25.5  49  3.7  208  15.7  44  3.3  37  2.8 
Affluent  1321  29.48  650  49.2  354  26.8  37  2.8  164  12.4  38  2.9  18  1.4 
County of Residence  p > 0.05  p > 0.05  p > 0.05  p > 0.05  p > 0.05  p > 0.05 
Hinds  4367  82.44  2472  56.7  1200  27.5 
21
6 
5.0  768  17.6  232  5.3  170  3.9 
Madison  498  9.40  244  49.0  158  31.7  23  4.6  80  16.1  27  5.2  13  2.6 
Rankin  232  4.38  107  46.3  54  23.4  8  3.5  28  12.1  7  3.0  5  2.2 
Unknown  200  3.78  97  48.5  48  24.0  15  7.5  35  17.5  4  2.0  7  3.5 
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Table 2 examines the medication adherence and non-adherence of the JHS African-American cohort 
based on the diagnoses of these conditions reported to them by a doctor. Of the five categories 
examined in this table, two categories, high blood pressure and diabetes, had high adherence rates of 
86.6% and 88.3% respectively. On the other hand, adherence rates for those JHS participants diagnosed 
with high cholesterol, heart problems, and strokes were exceptionally low. Only 13.0% of the African-
American participants in the JHS adhered to the recommended heart medications. Equally of concern 
was the adherence rate for JHS participants who were diagnosed with a stroke which was estimated at 
22.2%. JHS participants who were diagnosed with high cholesterol also demonstrated poor adherence 
rates with a rate of 39.7%. 
Table 2. Medication adherence by cardiovascular
 conditions of JHS participants at baseline. 
Cardiovascular 
Condition 
Took High 
Blood 
Pressure 
Medication 
Took 
Cholesterol 
Medication 
Took Heart 
Failure 
Medication 
Took 
Diabetes 
Medication 
Took 
Stroke 
Medication 
Told by Doctor had 
High Blood Pressure 
N = 2845 
Yes = 2464 
(86.6) 
No = 360 
(13.4) 
       
Told by Doctor had 
High Cholesterol 
N = 1405 
  Yes = 558 
(39.7) 
No = 844 
(60.1) 
     
Told by Doctor had 
Heart Attack 
N = 254 
    Yes = 33 
(13.0) 
No = 220 
(86.6) 
   
Told by Doctor had 
Diabetes 
N = 888 
      Yes = 784 
(88.3) 
No = 104 
(11.7) 
 
Told by Doctor had 
Stroke 
N = 189 
        Yes = 42 
(22.2) 
No = 147 
(77.8) 
 
Regression results indicated the overall fit of the predictors was moderate (−2 Log Likelihood = 
1591.993). The model was statistically reliable in distinguishing between hospitalization of JHS 
participants X
2 (6) = 45.050, p < 0.05. The model correctly classified 88.6% of the cases. Regression 
coefficients are presented in Table 3. Wald statistics indicated that the chance of being hospitalized for a 
CVD- related illness was increased for JHS participants who were female and those participants who 
did not adhere to their medication for treating chest pains and diabetes.  Int. J. Environ. Res. Public Health 2011, 8                 
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Table 3. Factors related to JHS hospitalization-regression coefficients. 
  B  S.E.  Wald  df  Sig.  Exp (B) 
Female 
 
Past 2 weeks, did not take medication 
for angina/chest pains 
Past 2 weeks, did not take medication 
for diabetes/high blood sugar 
Constant 
0.307 
 
−1.179 
 
−0.336 
 
−0.915 
0.148 
 
0.240 
 
0.148 
 
0.296 
4.290 
 
24.158 
 
5.191 
 
10.373 
1 
 
1 
 
1 
 
1 
0.038 
 
0.000 
 
0.023 
 
0.001 
1.359 
 
0.308 
 
0.714 
 
0.385 
 
Table 4 provides a ranking of the top ten reasons cited by the JHS participants for not taking their 
medications. The number one reason cited for creating this lapse in practice was that participants got in 
too much of a hurry and forgot to take their medications. Almost half of the participants (47.3%) 
recognized the busy lifestyle as a deterrent to maintaining a regular medical regimen. About one quarter 
of the participants (23.5%) believed that they could combat their medical issues without the aid of the 
prescriptions, and over 20.0% of the participants did not take their medications because the medications 
were not available to them. Approximately 19.0% participants of the JHS admitted that they did not 
take their medications because the medications made them feel bad. Over 18.0% of the JHS participants 
indicated that the high cost of living and the cost of medication made it difficult for them to acquire 
their prescriptions, and about 17.0% of them viewed the medication regimen as an obstacle to their 
normal daily activities. The discomforts they experienced prevented them from engaging in effective 
medical adherence. More than 13.0% of the participants believed that the prescribed medication created 
an inconvenience that they could not overcome and this caused them to become delinquent in their 
treatment regimen. About 10.0% of the participants had little faith in the efficacy of the medical regimen 
and desisted adherence, and 10.0% of the participants feared that they might become addicted to the 
medication so they refused to fill their prescriptions. In addition, 10.0% of the participants simply did 
not like taking medication, so they abstained from practicing adherence. 
Table 4. JHS participants’ top ten reasons for not taking medications. 
Top Ten Ranked Reasons  % 
1. In a hurry, too busy, forgot to take medications.  47.3 
2. Trying to do without taking medications.  23.5 
3. Did not have medication available.  21.1 
4. Medication made you feel bad-did not take.  18.9 
5. No money to purchase medication.  18.2 
6. Can’t carry out normal activities-did not take medications.  17.1 
7. Medication was inconvenient to take.  13.3 
8. Medication wouldn’t do any good-did not take.  10.5 
9. Thought you might become addicted-did not take medications.  10.3 
10. Don’t like to take medicine.  9.9 Int. J. Environ. Res. Public Health 2011, 8                 
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4. Conclusions 
A high adherence rate
 was found in this sample of 5301 for diabetes and high blood pressure 
medication in spite of the fact that African-Americans are less likely than whites to take prescribed 
medications, and African Americans with type 2 diabetes tend to have comparatively poor clinical 
outcomes. Even though the adherence rate for diabetes and hypertension medication was high, it is 
evident that there are still a considerable number of African-Americans who do not adhere to their daily 
medical regimen. The research also demonstrated that there are many African-Americans who do not 
trust the utility of the medications prescribed by their doctor. Observed disparities in outcomes for 
African-Americans could be attributed in part to the  low acceptance of evidence-based therapies, 
resulting in some degree of medication non adherence. It is evident that some participants do not accept 
the suggestion that daily compliance could reduce the need for subsequent medication and treatment to 
reduce the risk for complications. 
Belonging to the female gender and non-adherence of heart and stroke medication have been 
associated with a greater risk of hospitalization for CVD. In this study, these variables were seen as 
being  most strongly predictive of subsequent hospitalization. The percentage of participants
  not 
adherent to medication after being diagnosed with high cholesterol, heart failure, and stroke is high. A 
possible result of non-adherence is the worsening of medical conditions and other negative health 
outcomes. A majority of the Jackson Heart Study participants reported that they did not take their 
medications after having been diagnosed with stroke, cholesterol problems, and heart attacks. 
Inadequate preventive CVD care has been frequently cited as a contributing factor to negative   
health outcomes. 
These results can guide the initiation of quality improvement interventions to target   
African-American CVD patients who might be in  need of strong self-management guidance and 
support. Medication adherence should be a key component of any disease self-management plan that 
intends to present intervention strategies to effectively support constructive  preventive care. It is 
imperative that culturally sensitive education material be developed and implemented  to effectively 
manage CVD, and we propose the formation of support groups for promoting adherence to treatment 
among African Americans. The community should be exposed to information regarding eliminating the 
factors contributing to non-adherence to medical regimens for CVD as they relate to the reduction in 
health disparities and the reduction in morbidity, hospitalization and mortality among this   
African-American population. Our results provide evidence that adherence to prescribed medication is 
influenced by a multitude of factors, and we advocate strong support for interventions to increase 
medication adherence
 and decrease adverse
 outcomes so that patients can realize the full benefit of 
prescribed
 therapies and participate in improving the quality of their lives. Public health officials and 
medical practitioners must first identify those individuals who are at
 greatest risk for non-adherence and 
then develop a proactive management program that highlights daily medical compliance and persistence 
with the prescribed drug regimen. Int. J. Environ. Res. Public Health 2011, 8                 
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Limitations 
The main limitation of this study is the reliance on self-reported medication use and CVD conditions 
data. Participant differences in recall or reporting of medication use, health conditions, and 
hospitalization could influence the risk model.  
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